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Abstract
Background: Drug potency is a pharmacological parameter defining dose or concentration of drug required to
obtain 50% of the drug’s maximal effect. Pharmacokinetic-pharmacodynamic modelling and simulation allows
estimation of potency and evaluate strategies improving treatment outcome. The objective of our study is to
determine potency of atazanavir in hair, defined as atazanavir level in hair associated with 50% probability of failing
to achieve viral load below 1000 copies/ml among adolescents, and explore the effect of participant specific
variables on potency.
Methods: A secondary analysis was performed on data from a previous study conducted in HIV-infected
adolescents failing 2nd line ART from Harare central hospital, Zimbabwe, between 2015 and 2016. We simulated
atazanavir concentrations in hair using NONMEM (version 7.3) ADVAN 13, based on a previously established
pharmacokinetic model. Logistic regression methods were used for PKPD analysis. Simulations utilising PKPD model
focused on estimation of potency and exploring the effect of covariates.
Results: The potency of atazanavir in hair was found to be 4.5 ng/mg hair before adjusting for covariate effects.
Participants at three months follow-up, reporting adequate adherence, having normal BMI-for-age, and cared for by
mature guardians had increased potency of atazanavir in hair of 2.6 ng/mg, however the follow-up event was the
only statistically significant factor at 5% level.
Conclusion: Atazanavir in hair in the range 2.6 to 4.5 ng/mg is associated with above 50% probability of early viral
load suppression. Adherence monitoring to adolescents with lower potency of atazanavir is recommended. The
effect self-reported adherence level, BMI-for-age, and caregiver status require further evaluation.
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Background
The application of exposure-response analysis remains
very crucial in testing drug research or development
strategies in all phases. The exposure may be the dose or
a relevant pharmacokinetic (PK) measure such as drug
concentration. The response is referred to as the phar-
macodynamic (PD) outcome. If the exposure being used
is derived from a PK model, such exposure-response
analysis is also referred as PKPD modelling. Drug
potency is the dose or concentration of a drug required
to get 50% of that drug’s maximal effect, expressing the
intensity of drug activity. A drug that causes a response
to occur at a lower concentration has higher potency
and is desirable compared to a drug causing the same
response at a higher concentration [1].
Several models for exposure-response analysis estimate
potency using simple to more complex modelling. Logis-
tic regression is among the common methods used for
PKPD modelling of binary response. This approach has
been tested and advocated for use with the primary
focus of determining the effective concentration corre-
sponding to x-percent response (ECx) [2–7]. Although
some findings show that the accuracy of ECx estimates is
questionable, the use of the logit model remains one of
the robust methods to estimate the ECx values and al-
lows comparison of these values for different strategies
being tested [8–10].
The effective concentration relating to concentrations
that cause 50% of the maximum effect (EC50) defines the
concentration at which the curvature of the response
line occurs. The EC50 is a derived quantity estimated ro-
bustly, less dependent on the model accuracy, and is also
a commonly used quantitative pharmacodynamic param-
eter in testing the potency of drug treatment strategy
[11–16]. Additional parameters, such as EC80 or EC90 re-
lating to concentrations that cause 80 and 90%, respect-
ively, of the maximum effect are however also useful,
but they highly depend on model accuracy [17].
Several studies showed that antiretroviral drug con-
centrations in hair predict virologic treatment outcome
accurately. Some of these studies estimated antiretroviral
concentrations in hair and thresholds associated with
failing to suppress viral load derived using approaches
which cannot meet the minimal acceptable standards of
PKPD modelling [18–20]. The PKPD modelling ap-
proaches allow performance of simulation-based estima-
tions and to derive strategies that optimize treatment
outcome. Therefore, in this article, the aim is to establish
a reference range for atazanavir concentration in hair as-
sociated with higher probability of failing to achieve viral
load below 1000 copies/ml (i.e. potency) in adolescents
for clinical practice. In doing so, the objective is to fit a
PKPD model of the relationship between viral load and
PK model-based simulated atazanavir concentration in
hair, determine atazanavir in hair which corresponds to
50, 80 and 90% probabilities of treatment success, and
additionally to explore the participant specific variables
associated with a decrease in the EC50 value.
Method
Data source
Secondary analysis of data from a randomized clinical
trial comprising 50 adolescents on atazanavir/ritonavir-
based 2nd line antiretroviral therapy (ART) for at least
6 months was performed. In the primary study, partici-
pants were randomised to either modified directly
administered antiretroviral therapy arm (intervention) or
standard of care arm (control) and followed-up for 3
months. Informed consent questionnaires were used.
Viral load and hair samples were collected at baseline
and after 3 months follow-up [18]. Atazanavir concentra-
tions in hair were determined using the liquid chroma-
tography/mass spectrometry/mass spectrometry, with an
assay range of 0.05–20 ng/mg. The trial is registered
with the Pan African Clinical Trial Registry (PACT
R201502001028169) and NIH Clinical Trials.gov
(NCT02689895). The trial obtained ethical approval
from local institutions which include the Joint Research
Ethics Committee (JREC/51/14) and Medical Research
Council of Zimbabwe (MRCZ/A/1840). Steady-state ata-
zanavir concentrations in hair were simulated based pre-
viously established population PK model [21]. The PD
outcome was the actual measured viral load dichoto-
mised as below or above < 1000 copies/ml at three
months follow-up. In this study, we maintained covariate
effects that were significant in the population PK model.
PKPD modelling
Simple logistic regression was used to fit a relationship
between viral load below 1000 copies/ml and the simu-
lated atazanavir concentration in hair as the baseline
PKPD model. The probability of treatment failure (viral
load ≥1000 copies/ml) for a given a hair concentration
(X1) was estimated using the “predict” function in R-
statistical package which applies to eq. 1, where β0 is the
estimated regression constant, and β1 is the estimated
regression coefficient for the X1 variable.
Probability FailurejX1ð Þ ¼ e
β0þβ1X1½ 
1þ e β0þβ1X1½ 
ð1Þ
We performed multivariate logistic regression to ad-
just for covariate effects on the relationship between
viral load below 1000 copies/ml and the simulated
atazanavir concentration in hair as the covariate PKPD
model. Self-reported adherence, age-adjusted body mass
index (BMI-for-age), the study follow-up event, and
participant caregiver status were considered for testing
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based on contribution to the variability of atazanavir in
hair reported earlier [18, 21]. Covariates were included
in the full model if they exhibited the potential to de-
crease the EC50 value.
The probability of treatment failure was estimated for
given: hair concentration level (X1), self-reported adher-
ence measured by visual analogue scale (VAS) (X2),
BMI-for-age (X3) categorised in three groups as under-
weight (<5th percentile), normal (5th to <95th percent-
ile) and underweight (≥ 95th percentile), follow-up event
(X4), and participant caregiver status (X5) using the “pre-
dict” function in R-statistical package which apply eq. 2,
where β0 is the estimated regression constant, β1, β2, β3,
β4 and β5 are the estimated regression coefficients for
X1, X2, X3,X4 and X5 variables, respectively:
P FailurejX1;X2;X3;X4;X5ð Þ ¼ e
β0þβ1X1þβ2X2þβ3X3þβ4X4þβ5X5½ 
1þ e β0þβ1X1þβ2X2þβ3X3þβ4X4þβ5X5½ 
ð2Þ
Statistical significance of the covariates included in the
final model and comparison of accuracy among hier-
archical models were tested using analysis of variance
(ANOVA) at 5% level of significance as part of model
validation. Multicollinearity of the covariates included
was checked using the mean variance inflation factor
(VIF) value of less than 10 and there was no any rela-
tionship observed.
Simulation and determination of ECx values
We simulated the relationship between viral load and
atazanavir concentration in hair while adjusting for indi-
vidual covariate effects. The participant specific variables
that had a potential of decreasing the EC50 value were
used in simulation of the full covariate PKPD model.
Simulations were performed using the using the “pre-
dict” function in R-statistical package. Plot diagrams of
simulated concentration versus probability of treatment
failure including 95% confidence interval (CI) repre-
sented by shaded areas were constructed using the
“ggplot2” functions in R-statistical package. Graphical
interpolation was performed on the plots to determine
baseline ECx values and also to present the effect of indi-
vidual and multiple covariates on the EC50 value.
Results
Description of study data
The mean age was 15.8 years (standard deviation – 1.8)
and 54% were females. In terms of education, 89% had
completed secondary school, 9% completed primary
school and 2 were dropouts. About 54% had normal
BMI, 15% were overweight while 30% were underweight.
Regards to caregivers, 20% were biological parents, 40%
were grandparents, 10% were siblings and 30% were aunt
or uncle. About 32% were in the early WHO disease
progression stage at ART initiation, while 68% were of
the late stage. The mean adherence by visual analogue
scale (VAS) score was 84.2% (standard deviation – 18.1).
The median length of hair was 1 cm (range – 0.5 cm to
1.5 cm). The mean hair weight was 2 mg (standard devi-
ation – 0.15). Most of the study participants estimated
to be 82% were on tenofovir/lamivudine/atazanavir/rito-
navir drug combination. The mean (95% confidence
interval) simulated atazanavir concentration in hair was
1.2 (0.8–1.6) ng/mg hair and 2.2 (1.5–2.8) ng/mg hair at
enrolment and follow-up, respectively. The median
(interquartile range) of observed viral load was 70,676
(21,862 to 164,800) copies/ml and 8141 (< 40 to 82,250)
copies/ml at enrolment and follow-up, respectively. All
participants were adolescents with virologic treatment
failure (viral load ≥1000copies/ml) to atazanavir-based
2nd line ART at enrolment. About 40% of the study
participants became virologically suppressed (viral
load <1000copies/ml) after follow-up.
Baseline EC50, EC80 and EC90 values
The EC50 of atazanavir in hair was estimated to be
4.5 ng/mg hair with a 95% confidence interval of 3.5
to 7.6 ng/mg hair. The EC80 was estimated to be 6.5
ng/mg and a right-tailed 95% confidence interval with
a lower limit of 4.9 ng/mg hair, while the EC90 was
estimated to be 7.8 ng/mg hair and a right-tailed 95%
confidence interval with a lower limit of 7.8 ng/mg
hair. Figure 1 illustrates further the relationship be-
tween probability of failing to achieve viral load below
1000 copies/ml and the simulated atazanavir concen-
trations in hair.
Effect of self-reported adherence on EC50 value
The average EC50 for a participant with 100% self-
reported adherence was estimated to be approximately
equal to 4.5 ng/mg hair and a 95% confidence interval of
3.5 to 7.6 ng/mg hair. The average EC50 for a participant
with 50% self-reported adherence was estimated to be
approximately equal to 4.4 ng/mg hair and a right-tailed
95% confidence interval with a lower limit of 1.8 ng/mg
hair. The effect of 50% self-reported adherence on the
relationship between viral load and the simulated ataza-
navir concentrations in hair is illustrated further in
Fig. 2.
Effect of BMI-for-age on EC50 value
The average EC50 for normal BMI-for-age participants
was estimated to be approximately 3.8 ng/mg hair and
a 95% confidence interval of 2.7 to 6.8 ng/mg hair
compared to that for participants with normal BMI-
for-age. The average EC50 for overweight participants
was estimated to be approximately 3.5 ng/mg hair and
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a 95% confidence interval of 1.8 to 7.5 ng/mg hair
compared to that for participants with normal BMI-
for-age. The average EC50 for overweight participants
was estimated to be approximately 5.5 ng/mg hair and
a right-tailed 95% confidence interval with a lower
limit of 3.5 ng/mg hair compared to that for partici-
pants with normal BMI-for-age. Figure 3 shows
further the effect of normal BMI-for-age to the rela-
tionship between viral load and the simulated ataza-
navir concentrations in hair.
Effect of caregiver status on EC50 value
We estimated that the EC50 for participants who re-
ceived care from mature caregivers (≥ 19 years of age)
approximately decreased to 3.8 ng/mg hair and 95% con-
fidence interval of 2.3 to 6.4 ng/mg hair compared to
that for participants receiving care from younger siblings
(10 to 18 years). Figure 4 shows further the effect of re-
ceiving care from mature caregivers to the relationship
between viral load and the simulated atazanavir concen-
trations in hair.
Fig. 1 Exposure–response curve presenting the baseline relationship between probability of failing to achieve viral load suppression (dashed line)
including 95% confidence interval (shaded ribbon) and the simulated atazanavir concentrations in hair. The baseline EC50, EC80 and EC90 values
are illustrated on the plot (dashed arrows)
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Effect of the follow-up event status on EC50 value
The EC50 at the 3-months follow-up occasion was esti-
mated to be an average of 3.3 ng/mg hair and right-
tailed 95% confidence interval with a lower limit of 1.4
ng/mg hair compared to that for the same participants
at enrolment, irrespective of the study arm for these
subjects. Figure 5 illustrates further the effect of the
follow-up event to the relationship between viral load
and the simulated atazanavir concentrations in hair.
Effect of multiple covariates on EC50 value
The EC50 for these adolescents at 3-months follow-up
occasion, reporting adequate adherence, normal BMI-for-
age, and receiving care from mature caregivers concur-
rently was estimated to be approximately 2.6 ng/mg hair
and left-tailed 95% confidence interval with an upper limit
of 5.5 ng/mg hair. Figure 6 illustrates further the effect of
the multiple covariates on the relationship between viral
load and the predicted atazanavir concentrations in hair.
Fig. 2 Exposure–response curves presenting the baseline relationship between probability of failing to achieve viral load suppression (dashed
line) including 95% confidence interval (shaded ribbon) and the simulated atazanavir concentrations in hair, comparing with the effect of 50%
self-reported adherence to the relationship between probability of failing to achieve viral load suppression (dotted line) including 95% confidence
interval (shaded ribbon) and the simulated atazanavir concentrations in hair. The baseline and 50% self-reported adherence adjusted EC50 values
are illustrated on the plot (dashed and dotted arrows, respectively)
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Statistical significance of covariates on atazanavir
potency
The 3-months follow-up occasion reduced the EC50
value significantly at 5% level (p < 0.001), while all the
other covariates which were included in the full model
were not statistically significant at 5% level. Additional
information for the effect of individual covariate and the
multiple covariates concurrently (full model) are pre-
sented in Table 1.
Discussion
We performed the population analysis to explore the re-
lationship between atazanavir concentrations in hair and
virologic response in adolescents failing 2nd line ART
through the development of logistic regression models.
The exposure of interest used in this work was simulated
atazanavir concentrations based on our earlier work
[21]. Some previous work showed that mathematical
modelling can improve estimation of EC50 when steady-
Fig. 3 Exposure–response curves presenting the baseline relationship between probability of failing to achieve viral load suppression (dashed
line) including 95% confidence interval (shaded ribbon) and the simulated atazanavir concentrations in hair, comparing with the effect of normal
BMI-for-age to the relationship between probability of failing to achieve viral load suppression (dotted line) including 95% confidence interval
(shaded ribbon) and the simulated atazanavir concentrations in hair. The baseline and normal BMI-for-age adjusted EC50 values are illustrated on
the plot (dashed and dotted arrows, respectively)
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state simulations from a mathematical model are used,
hence it will be possible to interpret previously obtained
datasets again, and also to obtain accurate estimates of
EC50 even under circumstances where steady-state mea-
surements are not experimentally feasible [22].
The choice of using atazanavir in the model does not
have an association with the usefulness of drugs in clin-
ical practise, but merely because they were feasibly avail-
able to the authors during the modelling work. Although
the modelling results in this article add some knowledge
for clinical practise, a particular interest was also to
demonstrate a modelling framework usable to predict
treatment outcome based on a measure of drug expos-
ure obtained from hair. This approach can be extrapo-
lated or adopted for use to any other drug being used in
clinical practise. Drug exposure in hair has been found
to predict treatment outcomes better than any standard
measures known [23]. The fact that the PKPD model
Fig. 4 Exposure–response curves presenting the baseline relationship between probability of failing to achieve viral load suppression (dashed
line) including 95% confidence interval (shaded ribbon) and the simulated atazanavir concentrations in hair, comparing with the effect of mature
care-giver status to the relationship between probability of failing to achieve viral load suppression (dotted line) including 95% confidence
interval (shaded ribbon) and the simulated atazanavir concentrations in hair. The baseline and the mature care-giver status adjusted EC50 values
are illustrated on the plot (dashed and dotted arrows, respectively)
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has a dose component in its structural mechanism, a key
component to determine the need for dose
individualisation influenced the choice of the model
framework. However, evaluation of dose-adjustment
could not be performed in the current analysis because
of the low sample size (such that n < 30 for different
categories of the BMI-for-age).
The study 3-months follow-up occasion was the only
covariate that significantly improved potency of atazana-
vir in hair at 5% level of significance irrespective of the
study arm. This could be that by taking part in the clin-
ical trial, the participants had the knowledge that they
were under study, possibly influencing positively their
adherence to treatment and hence increasing their
chances of treatment success. There was no blinding in-
volved in the primary study during randomization of
study participants to study arms [24], hence increasing
the possibilities of bias. The covariates self-reported ad-
herence, BMI-for-age, and participant caregiver status
were included in the final model even though they were
Fig. 5 Exposure–response curves presenting the baseline relationship between probability of failing to achieve viral load suppression (dashed
line) including 95% confidence interval (shaded ribbon) and the simulated atazanavir concentrations in hair, comparing with the effect of the
follow-up event to the relationship between probability of failing to achieve viral load suppression (dotted line) including 95% confidence interval
(shaded ribbon) and the simulated atazanavir concentrations in hair. The baseline and the follow-up event adjusted EC50 values are illustrated on
the plot (dashed and dotted arrows, respectively)
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not significant at 5% level of significance, but because
they reduced the EC50 of atazanavir concentrations in
hair clinically significantly. Hence the individual effect of
these covariates needs further evaluation in the future
studies.
The simulations performed show that probabilities of
antiretroviral treatment success among those reporting
50% or 100% self-reported adherence is the same. How-
ever participants with 50% self-reported adherence had
wider confidence intervals compared to participants with
100% self-reported adherence which accurately predicted
treatment success the same as atazanavir concentration
in hair. This finding supports earlier findings which
showed that protease inhibitor levels in hair predict viro-
logic treatment outcome better than self-reported adher-
ence which provide information on exposure to a drug
of interest over a short period and is affected by recall
bias [19, 20, 25].
Participants with normal BMI-for-age improved po-
tency of atazanavir in hair while being either overweight
Fig. 6 Exposure–response curves presenting the baseline relationship between probability of failing to achieve viral load suppression (dashed
line) including 95% confidence interval (shaded ribbon) and the simulated atazanavir concentrations in hair, comparing with the effect of the 3-
months follow-up occasion, reporting adequate adherence, having normal BMI-for-age, and receiving care from mature caregivers concurrently
(dotted line) including 95% confidence interval (shaded ribbon) and the simulated atazanavir concentrations in hair. The baseline and the follow-
up event adjusted EC50 values are illustrated on the plot (dashed and dotted arrows, respectively)
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or underweight reduced potency during multivariate
analysis. This also concurs with earlier findings which
reported that normal to higher BMI is associated with
improved immunological health compared to lower BMI
[26–28]. Participants receiving care from mature care-
givers have increased chances of viral load suppression,
again supporting findings from previous studies. Their
findings highlighted the effect of caregiver maturity on
psychological distress to the complexity of perinatal
HIV-infection, chronic HIV disease and lifelong ART in
adolescents [29, 30].
The EC50 of atazanavir in hair for adolescents was esti-
mated to be 4.5 ng/mg hair before adjusting for covari-
ates effect. However the EC50 of atazanavir in hair was
optimally reduced to 2.4 ng/mg hair when the model
was simulated using participant specific variables that
had potential to reduce the value. The model-based opti-
mal estimate of the EC50 of atazanavir in hair concurs
with the result reported in the primary study which pro-
posed a cut-off of 2.35 ng/mg, the lower quartile of the
observed atazanavir concentration in hair among partici-
pants who achieved viral load suppression at 3-months
follow-up [18].
To the best of our knowledge, this is the first study to
apply mathematical modelling to establish cut-off points
for antiretroviral drugs measured in hair which are asso-
ciated with certain levels of the probability of viral load
suppression. Some covariates were reported in both the
bivariate and multivariate models on the basis of their
clinical significance even though they were not statisti-
cally significant. In this study, our 95% confidence inter-
vals of parameter estimates may look higher, which can
be attributed to the fact that both the PK [21] and the
PKPD modelling was based on a limited and small sam-
ple size (n = 50). Additionally, most of the simulated ata-
zanavir in hair concentrations were below the EC50,
EC80 and EC90 values based on the model projections
which is a sign of model over-prediction, something
which could have been influenced again by the limited
sample sizes It is important both future primary and
modelling studies which are going to be conducted to
collect a wide range factors that influence exposure-
response and also use a large sample size.
Conclusion
In conclusion, atazanavir in the hair in the range 2.4 to
4.5 ng/mg is likely associated with at least50% chances of
HIV suppression. Hair drug concentration predicts
chances of viral suppression more accurately when com-
pared to self-reported adherence. Direct monitoring of
dose ingestion is recommend for adolescents failing 2nd
line ART to improve chances of viral suppression. Also
specialised health-care interventions are recommended
for adolescents on ART whose caregivers are immature
to improve their chances of viral suppression. Dose-
adjustment require to be evaluated further especially for
underweight or overweight participants using PKPD
modelling.
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